Live Quote · OTCGCANHealthcare· Medical - Pharmaceuticals

The Greater Cannabis Company, Inc.

$0.19 0.00%(+$0.00)
TickerSpark Score
44/100
Weak
20
Valuation
35
Profitability
15
Growth
52
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GCAN research report →

52-Week Range38% of range
Low
$0.04
Current
$0.19
High
$0.45
Company Overviewwww.gcanrx.com

About the company

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body.

CEO
Aitan Zacharin
IPO
2018
Employees
1
HQ
Baltimore, MD, US

Price Chart

+96925.00% · this period
$0.45$0.23$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$183.37K
P/E
1940.50
P/S
0.00
P/B
-236.59
EV/EBITDA
-1.72
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
13.26%
ROIC
34.13%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-331,612 · -85.22%
EPS
$-0.40 · -199900.00%
Op Income
$-183,005
FCF YoY
45.06%
Performance & Tape
52W High
$0.45
52W Low
$0.04
50D MA
$0.18
200D MA
$0.17
Beta
0.38
Avg Volume
2.35K

Get TickerSpark's AI analysis on GCAN

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jul 31, 18ZACHARIN AITANother74,166,650
Apr 4, 25Sapir LLCother100,000,000
Dec 2, 19Anderson Jimmy Waynesell176,878
Nov 27, 19Anderson Jimmy Waynesell195,080
Jan 1, 19Anderson Jimmy Wayneother0
Jan 1, 19Anderson Jimmy Wayneother0
Oct 30, 07DEMEDIO DAVID Mother225,000
May 17, 07LEVI SHMUELother150,000
May 17, 07ORLEV CHAIMEother300,000
Feb 23, 07KATZ STEVENother1,150,000
Coverage · GCAN

Our GCAN coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on GCAN yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate GCAN report →
Internal Compare

Similar companies

Peers in the same neighborhood.